NASDAQ:SPROSpero Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spero Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.20 +0.31 (+2.61 %) (As of 05/28/2020 01:18 PM ET) Add Compare Share Today's Range$12.15Now: $12.21▼$12.3750-Day Range$7.51MA: $10.33▼$12.7552-Week Range$5.25Now: $12.21▼$14.38Volume95,513 shsAverage Volume204,850 shsMarket Capitalization$251.30 millionP/E RatioN/ADividend YieldN/ABeta2.03 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSpero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, Spero Therapeutics has a potential upside of 88.4% from its current price of $12.21.Amount of Analyst CoverageSpero Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesSpero Therapeutics has received 163 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSpero Therapeutics has received 145 “underperform” votes. (Add your “underperform” vote.)Community SentimentSpero Therapeutics has received 52.92% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote “Outperform” if you believe SPRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 18.34% of the stock of Spero Therapeutics is held by insiders.Percentage Held by Institutions52.88% of the stock of Spero Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spero Therapeutics are expected to grow in the coming year, from ($4.09) to ($3.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRO Previous Symbol CUSIPN/A CIK1701108 Websperotherapeutics.com Phone857-242-1600Debt Debt-to-Equity Ratio0.05 Current Ratio4.31 Quick Ratio4.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$18.15 million Price / Sales13.85 Cash FlowN/A Price / Cash FlowN/A Book Value$4.00 per share Price / Book3.05Profitability EPS (Most Recent Fiscal Year)($3.35) Net Income$-60,920,000.00 Net Margins-654.03% Return on Equity-88.22% Return on Assets-70.36%Miscellaneous Employees57 Outstanding Shares20,590,000Market Cap$251.30 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:SPRO Rates by TradingView Receive SPRO News and Ratings via Email Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions How has Spero Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Spero Therapeutics' stock was trading at $7.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SPRO stock has increased by 57.5% and is now trading at $12.2050. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Spero Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spero Therapeutics. When is Spero Therapeutics' next earnings date? Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Spero Therapeutics. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics Inc (NASDAQ:SPRO) released its quarterly earnings results on Friday, May, 8th. The company reported ($1.22) EPS for the quarter, beating the Zacks' consensus estimate of ($1.35) by $0.13. The business earned $1.70 million during the quarter, compared to the consensus estimate of $3.36 million. Spero Therapeutics had a negative net margin of 654.03% and a negative return on equity of 88.22%. View Spero Therapeutics' earnings history. What price target have analysts set for SPRO? 6 equities research analysts have issued 12-month price targets for Spero Therapeutics' shares. Their forecasts range from $20.00 to $28.00. On average, they anticipate Spero Therapeutics' stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 88.4% from the stock's current price. View analysts' price targets for Spero Therapeutics. Has Spero Therapeutics been receiving favorable news coverage? Press coverage about SPRO stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Spero Therapeutics earned a news impact score of 1.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutSpero Therapeutics. Are investors shorting Spero Therapeutics? Spero Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 536,900 shares, an increase of 6.5% from the April 15th total of 504,100 shares. Based on an average trading volume of 103,100 shares, the days-to-cover ratio is presently 5.2 days. Currently, 3.8% of the shares of the company are short sold. View Spero Therapeutics' Current Options Chain. Who are some of Spero Therapeutics' key competitors? Some companies that are related to Spero Therapeutics include Phibro Animal Health (PAHC), Athenex (ATNX), NextCure (NXTC), BioXcel Therapeutics (BTAI), Endo International (ENDP), Rhythm Pharmaceuticals (RYTM), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), ImmunoGen (IMGN), Gossamer Bio (GOSS), Cue Biopharma (CUE), Omeros (OMER), Passage Bio (ORIC), Collegium Pharmaceutical (COLL) and Nabriva Therapeutics (NBRV). View all competitors. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Crispr Therapeutics (CRSP), Viking Therapeutics (VKTX), Inovio Pharmaceuticals (INO), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), NVIDIA (NVDA), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Nokia Oyj (NOK) and Akoustis Technologies (AKTS). Who are Spero Therapeutics' key executives? Spero Therapeutics' management team includes the following people: Dr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 39, Pay $747.88k)Ms. Cristina Larkin, Chief Operating Officer (Age 50, Pay $552.96k)Dr. David A. Melnick M.D., Chief Medical Officer (Age 68, Pay $545.96k)Mr. Stephen J. DiPalma M.B.A., Interim CFO & Treasurer (Age 61)Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 66) When did Spero Therapeutics IPO? (SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. What is Spero Therapeutics' stock symbol? Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO." Who are Spero Therapeutics' major shareholders? Spero Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.34%), Rock Springs Capital Management LP (2.94%), VR Adviser LLC (2.30%), State Street Corp (1.37%), Granahan Investment Management Inc. MA (0.84%) and Geode Capital Management LLC (0.75%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View institutional ownership trends for Spero Therapeutics. Which major investors are selling Spero Therapeutics stock? SPRO stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., UBS Group AG, and Deutsche Bank AG. View insider buying and selling activity for Spero Therapeutics. Which major investors are buying Spero Therapeutics stock? SPRO stock was acquired by a variety of institutional investors in the last quarter, including VR Adviser LLC, BlackRock Inc., Rock Springs Capital Management LP, State Street Corp, DAFNA Capital Management LLC, Dupont Capital Management Corp, Geode Capital Management LLC, and Granahan Investment Management Inc. MA. View insider buying and selling activity for Spero Therapeutics. How do I buy shares of Spero Therapeutics? Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Spero Therapeutics' stock price today? One share of SPRO stock can currently be purchased for approximately $12.21. How big of a company is Spero Therapeutics? Spero Therapeutics has a market capitalization of $251.30 million and generates $18.15 million in revenue each year. The company earns $-60,920,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Spero Therapeutics employs 57 workers across the globe. What is Spero Therapeutics' official website? The official website for Spero Therapeutics is sperotherapeutics.com. How can I contact Spero Therapeutics? Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected] This page was last updated on 5/28/2020 by MarketBeat.com Staff
